Advertisement
MCP
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/mcp.M400008-MCP200 on May 28, 2004.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
M400008-MCP200v1
3/8/820    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Glossary
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lin, Z.
Right arrow Articles by Elenitoba-Johnson, K. S. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lin, Z.
Right arrow Articles by Elenitoba-Johnson, K. S. J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Molecular & Cellular Proteomics 3:820-833, 2004.
© 2004 by The American Society for Biochemistry and Molecular Biology, Inc.

Research

Quantitative Proteomic and Transcriptional Analysis of the Response to the p38 Mitogen-activated Protein Kinase Inhibitor SB203580 in Transformed Follicular Lymphoma Cells*,S

Zhaosheng Lin{ddagger}, David K. Crockett{ddagger}, Stephen D. Jenson§, Megan S. Lim{ddagger},§ and Kojo S. J. Elenitoba-Johnson{ddagger},§,¶

From the {ddagger} Associated Regional and University Pathologists (ARUP) Institute for Clinical and Experimental Pathology and § Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT 84132

The p38 mitogen-activated protein kinase (MAPK) is a key mediator of stress, extracellular-, growth factor-, and cytokine-induced signaling, and has been implicated in the development of cancer. Our previous work showed evidence for p38 MAPK activation in a subset of transformed follicular lymphomas (Elenitoba-Johnson et al. (2003) Proc. Natl. Acad. Sci. U.S.A. 100, 7259). We demonstrated that inhibition of p38 MAPK by SB203580 resulted in dose- and time-dependent caspase-3-mediated apoptosis. In order to further elucidate the basis of the cellular effects of SB203580, we have employed a systems biologic approach involving cDNA microarray and quantitative proteomic analysis of transformed follicular lymphoma derived-cells (OCI Ly-1) treated with SB203580. Gene expression profiling revealed differential expression (≥1.5-fold) of 374 genes/ESTs in cells treated for 3 h and 515 genes/ESTs in cells treated for 21 h. The majority (52% at 3 h and 91% at 21 h) were down-regulated, including genes encoding growth cytokines, transcriptional regulators and cytoskeletal proteins. Quantitative proteomic analysis using ICAT-LC-MS/MS identified 277 differentially expressed proteins at 3 h and 350 proteins at 21 h of treatment with SB203580, the majority of which were also down-regulated. Analysis of functional groups of the differentially expressed proteins implicated components of diverse overlapping pathways including the IL-6/phosphatidylinositol 3-kinase, insulin-like growth factor 2/Ras/Raf, WNT8d/Frizzled, MAPK-activated protein kinase 2, and nuclear factor {kappa}B. The differential phosphorylation status of selected kinase-active proteins was validated by Western blotting analysis. Our complementary genomic and proteomic approach reveal the global cellular consequences of SB203580 treatment and provide insights into its growth inhibitory effect on transformed follicular lymphoma cells.

To whom correspondence should be addressed: Division of Anatomic Pathology, University of Utah Health Sciences Center, 50 North Medical Drive, Salt Lake City, UT 84132. Tel.: 801-585-7082; Fax: 801-585-3831; E-mail: kojo.elenitobaj{at}path.utah.edu


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 BloodHome page
M. S. Lim, M. L. Carlson, D. K. Crockett, G. C. Fillmore, D. R. Abbott, O. F. Elenitoba-Johnson, S. R. Tripp, G. Z. Rassidakis, L. J. Medeiros, P. Szankasi, et al.
The proteomic signature of NPM/ALK reveals deregulation of multiple cellular pathways
Blood, August 20, 2009; 114(8): 1585 - 1595.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. GenomicsHome page
C. Zer, G. Sachs, and J. M. Shin
Identification of genomic targets downstream of p38 mitogen-activated protein kinase pathway mediating tumor necrosis factor-{alpha} signaling
Physiol Genomics, October 19, 2007; 31(2): 343 - 351.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
O. Tenhunen, J. Rysa, M. Ilves, Y. Soini, H. Ruskoaho, and H. Leskinen
Identification of Cell Cycle Regulatory and Inflammatory Genes As Predominant Targets of p38 Mitogen-Activated Protein Kinase in the Heart
Circ. Res., September 1, 2006; 99(5): 485 - 493.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Hachem and R. B. Gartenhaus
Oncogenes as molecular targets in lymphoma
Blood, September 15, 2005; 106(6): 1911 - 1923.
[Full Text] [PDF]

Home page
 ASH Education BookHome page
A. S. Freedman
Biology and Management of Histologic Transformation of Indolent Lymphoma
Hematology, January 1, 2005; 2005(1): 314 - 320.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Journal of Biological Chemistry 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2004 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement